McDermott Will & Schulte has advised Deep Track Capital. Hemab Therapeutics, a clinical-stage biotechnology company specializing in the development of novel prophylactic therapeutics for underserved bleeding…
Deep Track Capital Invests in Hemab Therapeutics’ $157 Million Series C Financing
